New Results
Peptide Antidotes to SARS-CoV-2 (COVID-19)
View ORCID ProfileAndre Watson, View ORCID ProfileLeonardo Ferreira, View ORCID ProfilePeter Hwang, View ORCID ProfileJinbo Xu, View ORCID ProfileRobert Stroud
doi: https://doi.org/10.1101/2020.08.06.238915
Andre Watson
1Ligandal Inc., San Francisco, CA, USA
Leonardo Ferreira
2Diabetes Center, University of California San Francisco, San Francisco, CA, USA
3Department of Surgery, University of California San Francisco, San Francisco, CA, USA
Peter Hwang
4Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA
Jinbo Xu
5Toyota Technological Institute, Chicago, IL, USA
Robert Stroud
4Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA
Posted August 06, 2020.
Peptide Antidotes to SARS-CoV-2 (COVID-19)
Andre Watson, Leonardo Ferreira, Peter Hwang, Jinbo Xu, Robert Stroud
bioRxiv 2020.08.06.238915; doi: https://doi.org/10.1101/2020.08.06.238915
Subject Area
Subject Areas
- Biochemistry (11755)
- Bioengineering (8757)
- Bioinformatics (29209)
- Biophysics (14980)
- Cancer Biology (12103)
- Cell Biology (17416)
- Clinical Trials (138)
- Developmental Biology (9425)
- Ecology (14187)
- Epidemiology (2067)
- Evolutionary Biology (18314)
- Genetics (12246)
- Genomics (16807)
- Immunology (11870)
- Microbiology (28101)
- Molecular Biology (11599)
- Neuroscience (60995)
- Paleontology (452)
- Pathology (1872)
- Pharmacology and Toxicology (3238)
- Physiology (4961)
- Plant Biology (10429)
- Synthetic Biology (2887)
- Systems Biology (7341)
- Zoology (1651)